来那度胺致多发性骨髓瘤患者静脉血栓形成的机制

来那度胺是一种新型的免疫调节药物,已被广泛应用于治疗多发性骨髓瘤,但其所致静脉血栓形成的副作用也越来越明显。当单独使用来那度胺治疗多发性骨髓瘤时,患者静脉血栓的发生率比较低,而其与地塞米松、化疗药物等联合使用治疗多发性骨髓瘤时,静脉血栓的发生率明显高于单独使用。来那度胺致多发性骨髓瘤患者静脉血栓形成的机制目前尚未完全阐明,国内外研究显示,其主要与内皮细胞功能紊乱、组织因子与磷脂酰丝氨酸暴露增加及体内的高凝状态相关。本文主要就来那度胺致多发性骨髓瘤患者静脉血栓形成的机制进行了简要综述。

Mechanismof Lenalidomid induced the Venous Thrombosis in Patients with Multiple Myeloma

Lenalidomid, a novel immunomodulatory drug, has been widely used in the treatment of the patients with multiple myeloma (MM), but the side effects of venous thrombosis (VTE) is becoming more and more obvious. The incidence of VTE in the patients with MM who recieved lenalidomid alone is low. But the increased incidence of VTE is observed when lenalidomid is given in combination with dexamesone or chemotherapy. The mechanism of formation of VTE is still unclear until now. Recent researches at home and abroad mainly include endothelial dysfunction, the increase of tissue factor and phosphatidylserine exposure and hypercoagulable state in the body. This article is aimed to review the research progress on the mechanism of lenalidomid induced the venous thrombosis in patients with MM.